Press Releases

Date Title
08/05/20
Summary ToggleT2 Biosystems Announces Withdrawal of Proxy Statement Proposal to Amend Its Certificate of Incorporation to Authorize a Possible Reverse Stock Split Printer Friendly Version LEXINGTON, Mass. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that its Board of Directors has decided it will not seek authority from the stockholders at the 2020 Annual Meeting (“Annual Meeting”)
07/30/20
Summary ToggleT2 Biosystems to Participate in the Canaccord Genuity Annual Growth Conference Printer Friendly Version LEXINGTON, Mass. , July 30, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate in the upcoming virtual Canaccord Genuity Annual Growth Conference.
07/28/20
Summary ToggleT2 Biosystems to Report Second Quarter 2020 Financial Results on August 11, 2020 Printer Friendly Version LEXINGTON, Mass. , July 28, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the second quarter of 2020 after market close on Tuesday, August 11, 2020.
06/30/20
Summary ToggleT2 Biosystems Announces U.S. Launch of COVID-19 Diagnostic Test Printer Friendly Version The T2SARS-CoV-2™ Panel will run on the FDA cleared T2Dx® Instrument LEXINGTON, Mass. , June 30, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the completion of validation of its COVID-19 molecular
06/30/20
Summary ToggleT2 Biosystems Announces Preliminary Second Quarter 2020 Financial Results Printer Friendly Version Launches the T2SARS-CoV-2™ Panel under FDA EUA Guidelines LEXINGTON, Mass. , June 30, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced unaudited preliminary financial result estimates for the quarter ended June
06/26/20
Summary ToggleT2 Biosystems Reports Granting of Inducement Award Printer Friendly Version LEXINGTON, Mass. , June 26, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to four new employees. The awards were made on May 5, 2020 and June 2, 2020 under T2 Biosystems’
06/17/20
Summary ToggleT2 Biosystems Regains Compliance with NASDAQ Listing Requirements Printer Friendly Version LEXINGTON, Mass. , June 17, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that on June 16, 2020 it received written notice from the Nasdaq Listing Qualifications Staff of the NASDAQ Stock Market LLC
06/15/20
Summary ToggleT2 Biosystems Announces Changes to Board of Directors Printer Friendly Version Three new appointments add significant clinical and commercialization experience and expand board diversity LEXINGTON, Mass. , June 15, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced three new Board of
05/19/20
Summary ToggleT2 Biosystems’ Bacteria Panel Wins “Best New Technology Solution - Diagnostics" Award in MedTech Breakthrough Awards Printer Friendly Version Achievement Underscores the Clinical Value of Company’s Rapid Diagnostic Test for Sepsis-causing Bacterial Pathogens in Bloodstream LEXINGTON, Mass. , May 19, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced it
05/05/20
Summary ToggleT2 Biosystems Announces First Quarter 2020 Financial Results Printer Friendly Version LEXINGTON, Mass. , May 05, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems , Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the first quarter ended March 31, 2020 . Recent Highlights Achieved first quarter total revenue of $2.5 million